CAR-T cell therapies infused into brain shrink tumors in two glioblastoma studies
Two groups of researchers say that experimental CAR-T cell therapies have shrunk tumors in a matter of days in patients with recurrent glioblastoma, a deadly brain cancer, who got a single infusion of the engineered cells directly into their heads earlier this year.
Both teams treated patients whose cancer came back despite previous treatments like chemotherapy, radiation and surgery, and many had multiple tumors scattered throughout their brains. The interim results from the two ongoing Phase I studies for just three patients each were presented Sunday at the Society for NeuroOncology’s annual meeting in Vancouver.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
